Ella R. Thompson

4.7k total citations · 1 hit paper
67 papers, 2.7k citations indexed

About

Ella R. Thompson is a scholar working on Genetics, Cancer Research and Molecular Biology. According to data from OpenAlex, Ella R. Thompson has authored 67 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 26 papers in Cancer Research and 21 papers in Molecular Biology. Recurrent topics in Ella R. Thompson's work include Cancer Genomics and Diagnostics (20 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Myeloid Leukemia Research (13 papers). Ella R. Thompson is often cited by papers focused on Cancer Genomics and Diagnostics (20 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Myeloid Leukemia Research (13 papers). Ella R. Thompson collaborates with scholars based in Australia, United Kingdom and China. Ella R. Thompson's co-authors include Ian Campbell, Kylie L. Gorringe, Piers Blombery, Georgina L. Ryland, Jason Li, Alison H. Trainer, Paul A. James, Maria Doyle, Andrew W. Roberts and David Y.H. Choong and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ella R. Thompson

60 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Ella R. Thompson

Since Specialization

Citations

This map shows the geographic impact of Ella R. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ella R. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ella R. Thompson more than expected).

Fields of papers citing papers by Ella R. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ella R. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ella R. Thompson. The network helps show where Ella R. Thompson may publish in the future.

Co-authorship network of co-authors of Ella R. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Ella R. Thompson. A scholar is included among the top collaborators of Ella R. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ella R. Thompson. Ella R. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrative analysis of the tumour immune microenvironment of breast implant-associated anaplastic large cell lymphoma using multi-omics 2025 ·Blood ·Criselle D’Souza, Niko Thio, (unknown), Heshani Desilva, Piers Blombery, Ella R. Thompson, Anand K. Deva, H. Miles Prince, Paul J. Neeson	0
2	Genomic variation in DDX41 identified through clinical sequencing 2025 ·British Journal of Haematology ·(unknown), Ing Soo Tiong, Sally M. Hunter, Nicole den Elzen, (unknown), (unknown), (unknown), Ella R. Thompson, Michelle Tan, (unknown), Lucy C. Fox, Piers Blombery	0
3	Biallelic deleterious germline SH2B3 variants cause a novel syndrome of myeloproliferation and multi‐organ autoimmunity 2023 ·SHILAP Revista de lepidopterología ·Piers Blombery, Vahid Pazhakh, Adriana S. Albuquerque, Jesmeen Maimaris, (unknown), (unknown), (unknown), Ella R. Thompson, Ben Carpenter, Ian Proctor, Julie Curtin, Jonathan Lambert, Siobhan O. Burns, Graham J. Lieschke	8
4	Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma 2023 ·Blood ·(unknown), (unknown), Mark R. Dowling, Javad Saghebi, (unknown), Roxane Legaie, (unknown), (unknown), (unknown), (unknown), Stephanie J. Yaung, (unknown), (unknown), Michael Dickinson, Ella R. Thompson, Piers Blombery	1
5	The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing 2023 ·Blood Advances ·Anna Maierhofer, Nikita Mehta, Ryan A. Chisholm, Stephan Hütter, Constance Baer, Niroshan Nadarajah, Christian Pohlkamp, Ella R. Thompson, Paul A. James, Wolfgang Kern, Claudia Haferlach, Manja Meggendorfer, Torsten Haferlach, Piers Blombery	9
6	Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients 2023 ·Neurology and Therapy ·Jonathan D. Santoro, (unknown), Zoya Panahloo, Ella R. Thompson, (unknown), Jacqueline Palace	10
7	Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia 2023 ·Applied Health Economics and Health Policy ·(unknown), Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman, Maarten J. IJzerman	1
8	SOHO State of the Art Updates and Next Questions \| Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions 2022 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Ella R. Thompson, Constantine S. Tam	12
9	Transient, flexible gene editing in zebrafish neutrophils and macrophages for determination of cell-autonomous functions 2021 ·Disease Models & Mechanisms ·(unknown), Zuobing Zhang, Vahid Pazhakh, (unknown), Ella R. Thompson, Lucy C. Fox, (unknown), Piers Blombery, Graham J. Lieschke	11
10	Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors 2021 ·Blood Advances ·Ella R. Thompson, Tamia Nguyen, (unknown), John Markham, Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David Westerman, Piers Blombery	17
11	Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes 2020 ·Haematologica ·Piers Blombery, Lucy C. Fox, Georgina L. Ryland, Ella R. Thompson, (unknown), Michelle McBean, (unknown), David J. Hughes, Anthea Greenway, Françoise Méchinaud, Erica M. Wood, Graham J. Lieschke, Jeff Szer, Pasquale Barbaro, (unknown), Joel Wight, Elly Lynch, Melissa Martyn, Clara Gaff, David Ritchie	11
12	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study 2019 ·Cancer Discovery ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John K. C. Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison	132
13	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia breakdown → 2018 ·Cancer Discovery ·Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts	276
14	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 2017 ·Leukemia ·(unknown), (unknown), Donia M. Moujalled, David Segal, Giovanna Pomilio, Sewa Rijal, Anissa M. Jabbour, Katherine D. Cummins, Kurt Lackovic, Piers Blombery, Ella R. Thompson, Paul G. Ekert, Guillaume Lessène, Stefan Glaser, David C.S. Huang, Andrew W. Roberts, Mark A. Guthridge, Andrew H. Wei	124
15	Copy number analysis of ductal carcinoma in situ with and without recurrence 2015 ·Modern Pathology ·Kylie L. Gorringe, Sally M. Hunter, Jia‐Min Pang, Ken Opeskin, Prue Hill, Simone M. Rowley, David Y.H. Choong, Ella R. Thompson, Alexander Dobrovic, Stephen B. Fox, G. Bruce Mann, Ian Campbell	31
16	Bioinformatics Pipelines for Targeted Resequencing and Whole-Exome Sequencing of Human and Mouse Genomes: A Virtual Appliance Approach for Instant Deployment 2014 ·PLoS ONE ·Jason Li, Maria Doyle, Isaam Saeed, Stephen Q. Wong, Victoria Mar, David L. Goode, Franco Caramia, Ken Doig, Georgina L. Ryland, Ella R. Thompson, Sally M. Hunter, Saman Halgamuge, Jason Ellul, Alexander Dobrovic, Ian Campbell, Anthony T. Papenfuss, Grant A. McArthur, Richard W. Tothill	18
17	Genome-Wide, High-Resolution Detection of Copy Number, Loss of Heterozygosity, and Genotypes from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Microarrays 2007 ·Cancer Research ·Sharoni Jacobs, Ella R. Thompson, Yasuhito Nannya, Go Yamamoto, Raji Pillai, Seishi Ogawa, Dione K. Bailey, Ian Campbell	65
18	High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications 2007 ·Clinical Cancer Research ·Kylie L. Gorringe, Sharoni Jacobs, Ella R. Thompson, Anita Sridhar, Wen Qiu, David Y.H. Choong, Ian Campbell	122
19	High resolution SNP array analysis of primary ovarian tumors reveals numerous microdeletions and amplifications. 2007 ·Clinical Cancer Research ·Ian Campbell, Sharoni Jacobs, Ella R. Thompson, Kylie L. Gorringe	0
20	A novel duplication polymorphism in the FANCApromoter and its association with breast and ovarian cancer 2005 ·BMC Cancer ·Ella R. Thompson, (unknown), Sally‐Anne Stephenson, Diana Eccles, Ian Campbell, Alexander Dobrovic	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact